Increased Utilization of Positron Emission Tomography–Computed Tomography (PET/CT) Imaging and Its Economic Impact for Patients Diagnosed with Bladder Cancer

Jinhai Huo¹, Yiyi Chu¹, Karim Chamie², Marc C. Smaldone³, Stephen A. Boorjian⁴, Jacques G. Baillargeon⁵, Yong-Fang Kuo⁶, Preston Kerr⁷, Padraic O'Malley⁸, Eduardo Orihuela⁷, Douglas S. Tyler⁹, Stephen J. Freedland¹⁰, Sharon H. Giordano¹, Raghu Vikram¹¹, Ashish M. Kamat¹², and Stephen B. Williams⁷

¹Department of Health Services Research, The University of Texas MD Anderson Cancer Center, Houston, TX

²Department of Urology, University of California Los Angeles, Los Angeles, CA

³Department of Urology, Fox Chase Cancer Center, Philadelphia, PA

⁴Department of Urology, Mayo Clinic, Rochester, MN

⁵Department of Medicine, Division of Epidemiology, Sealy Center on Aging, The University of Texas Medical Branch at Galveston, Galveston, TX

⁶Department of Medicine, Division of Biostatistics, Sealy Center on Aging, Sealy Center on Aging, The University of Texas Medical Branch at Galveston, Galveston, TX

⁷Division of Urology, The University of Texas Medical Branch at Galveston, Galveston, TX

⁸Department of Urology, Dalhousie University, Halifax, Nova Scotia, Canada

⁹Department of Surgery, The University of Texas Medical Branch at Galveston, Galveston, TX

¹⁰Department of Urology, Cedars Sinai Medical Center, Los Angeles, CA

¹¹Department of Diagnostic Radiology, The University of Texas MD Anderson Cancer Center, Houston, TX

¹²Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX

Abstract

Background—To examine temporal nationwide utilization patterns and predictors for use of positron emission tomography–computed tomography (PET/CT) in comparison to magnetic

Corresponding author: Stephen B. Williams, MD, The University of Texas Medical Branch, Division of Urology, 301 University Blvd, Galveston, TX 77555, P: 409-747-7333, F: 409-772-0088, stbwilli@utmb.edu.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Conflict of Interest: None

resonance imaging (MRI) and computed tomography (CT) among patients diagnosed with bladder cancer.

Materials and Methods—A total of 36,855 patients aged 66 years or older diagnosed with clinical stage T1-IV, N0M0 bladder cancer from 2004 to 2011 were analyzed. We used multivariable logistic regression analyses to discern factors associated with receipt of imaging within 12 months from diagnosis. The Cochran-Armitage test for trend was used to determine changes in the proportion of patients receiving imaging after cancer diagnosis.

Results—Independent of clinical stage, there was marked increase in use of PET/CT throughout the study period (2011 v 2004: OR 17.55, 95% CI = 10.14–30.38, $P < 0.001$). While use of CT imaging remained stable during the study period, there was significantly decreased utilization of MRI (OR 0.60, 95% CI 0.49–0.75, $P < 0.001$) in 2011 vs. 2004. The mean incremental cost of PET/CT versus CT and MRI was \$1,040 and \$612 (in 2016 dollars), respectively. Extrapolating these findings to the bladder cancer patients in U.S. results in excess spending of \$11.6 million for PET/CT imaging.

Conclusion—We identified rapid adoption of PET/CT imaging independent of clinical stage, resulting in excess national spending of \$11.6 million for this imaging modality alone. Further value-based research discerning the clinical versus economic benefits of advanced imaging among bladder cancer patients are needed.

Keywords

Imaging; positron emission tomography–computed tomography; PET/CT; bladder cancer

INTRODUCTION

There were an estimated 76,960 new cases and 16,390 deaths from bladder cancer in the United States in 2016¹. Clinical staging for bladder cancer commonly includes transurethral resection of the bladder tumor and upper tract imaging^{2–4}. Imaging techniques such as positron emission tomography–computed tomography (better known as PET-CT or PET/CT), magnetic resonance imaging (MRI), and computed tomography (CT) can improve preoperative staging and follow-up surveillance.

Prior studies have explored the utility of PET/CT imaging in primary bladder cancer with limited evidence suggesting clinical superiority^{5–7}. Moreover, meta-analyses have suggested PET/CT is ‘good’ in detecting metastatic disease but could not recommend this as the preferred imaging modality over other imaging due to limited studies and lack of comparative effectiveness research⁷. Taking the above into account, current guidelines recommend CT and/or MRI as the preferred abdominal imaging modality in staging bladder cancer patients^{2–4}.

The American Board of Internal Medicine’s Choosing Wisely campaign and American Society of Clinical Oncology’s Value of Cancer Care Task Force have collaborated to encourage sustainable high-quality and high-value based cancer care⁸. Widespread adoption of costlier advanced imaging modalities such as PET/CT with lack of well-documented superiority over other imaging techniques can have a significant impact on the national

health care system. Indeed, the Institute of Medicine recently conveyed a workshop aimed at controlling use of expensive advanced cancer care and treatments in the absence of comparative effectiveness research documenting superiority over less costly alternatives⁹. Utilization patterns regarding advanced imaging in bladder cancer remain largely unknown. Given this void in understanding we used a large population-based cancer registry to analyze utilization trends and costs associated with advanced imaging in bladder cancer patients.

METHODS

Database

We used the Surveillance, Epidemiology, and End Results (SEER) Medicare-linked database. The SEER registry, supported by the National Cancer Institute, contains patients' demographic and cancer diagnosis information for approximately 30% of the U.S. population from 18 geographic regions, including Alaska, Arizona, Cherokee Nation, Connecticut, Detroit, Georgia, San Francisco-Oakland, San Jose-Monterey, Greater California, Hawaii, Iowa, Kentucky, Los Angeles, Louisiana, New Jersey, New Mexico, Seattle-Puget Sound, and Utah. The Medicare program contains health care claims and payments for 97% of US citizens age 65 and over. The SEER registry data is linked with Medicare claims data using a unique encrypted patient identifier.

Patient-Selection Criteria

The study population consisted of patients aged 66 years and older with an incident of bladder cancer diagnosed with clinical stage I to IV, N0, M0 transitional cell or urothelial carcinoma (American Joint Committee on Cancer Modified third edition; ICD-O-3 codes 8120 and 8130) from January 1, 2004 through December 31, 2011. We excluded the following patients: those with a bladder cancer diagnosis from a death certificate or autopsy, those without pathological confirmation, those without continuous Part A and Part B insurance coverage within 12 months of their cancer diagnosis, those without continuous Part A and Part B insurance coverage until death, and finally those that had health maintenance organization enrollment during the same period (Supplemental Material 1).

Identification of Imaging Modalities

The primary outcome of this study was receipt of imaging which included CT, MRI and/or PET/CT, for the purpose of diagnosis and surveillance. This was determined using Medicare claims data within one year after the date of bladder cancer diagnosis. We identified the three imaging modalities using the following HCPCS codes: PET/CT (78815 and 78816), MRI (74181–74183, 74185, 76498, and 72195–72197), and CT (codes 72191–72194, 74150–74170, 74176–74178, and 76497).

Patient Characteristics

Patient demographic information included age at cancer diagnosis (66–69, 70–74, 75–79, and 80 years or older), year of cancer diagnosis, race/ethnicity (non-Hispanic white, non-Hispanic black, Hispanic, and other), marital status (single, married, and unknown), US census region (West, Northeast, Midwest and South), and neighborhood median household income (categorized into quartiles). Tumor characteristics, as reported by SEER data,

included clinical stage, histologic grade and presence of hydronephrosis. We used the modification by Klabunde et al of the Charlson Comorbidity Index to quantify severity of preexisting comorbidities^{10, 11}. Treatment within one year after bladder cancer diagnosis was determined from the Medicare claims using both ICD (ninth revision) procedure codes and level II Healthcare Common Procedure Coding System (HCPCS): Current Procedural Terminology (CPT) codes (Supplemental Material 2).

Cost Analysis

We measured the Medicare payments to these three imaging modalities within one year after bladder cancer diagnosis, and all reported costs were adjusted and normalized to 2016 U.S. dollars using the medical care component of the Consumer Price Index¹². We also extrapolated the national excess medical spending on advanced imaging for bladder cancer care. Using the estimated nationwide new cases of bladder cancer in 2016 from the SEER registry and its stage distribution, we multiplied the number of patients in each stage group by the proportion expected to receive the imaging. Finally, the number of patients who received advanced imaging was multiplied by the mean differences of costs between advanced imaging (PET/CT) and the two imaging modalities (CT and MRI).

Statistical Analysis

We compared use of imaging modalities in bladder cancer patients stratified by demographic and clinical variables with Pearson χ^2 tests. We performed a Cochran-Armitage test for trend to assess changes in the proportion of patients receiving imaging after cancer diagnosis, and also the various types of imaging modalities utilized from 2004 to 2011. Multivariable logistic regression models were used to determine adjusted odds ratios for use of the three imaging modalities. We assessed goodness-of-fit using the Hosmer and Lemeshow test. All statistical analyses were conducted using the SAS (version 9.4; SAS Institute, Cary, NC, USA) software suite. The criterion for statistical significance was a *P* value less than 0.05. Our study was exempted for approval by The University of Texas MD Anderson Cancer Center and The University of Texas Medical Branch Institutional Review Boards.

RESULTS

Patient demographics and clinical characteristics according to imaging modality are presented in Table 1. In total, 24,240 (65.8%) patients received one of these three imaging modalities within 12 months after bladder cancer diagnosis: 1,291 (3.5%) PET/CT, 1,495 (4.1%) MRI, and 21,454 (58.2%) CT. We also observed a greater use of PET/CT among female patients, residents in West region, patients diagnosed with hydronephrosis or high grade tumor, and patients who underwent surgery, chemotherapy, or radiation therapy.

When assessing trends in receipt of imaging, the use of PET/CT significantly increased over the time period of study, from < 0.5% in 2004 to 4.4% in 2011 (*P* trend < 0.001). At the same time, the percentage of patients who received an MRI significantly decreased over the study period (*P* trend < 0.001) (Figure 1). We further assessed trends in receipt of imaging according to clinical stage (Figure 2). PET/CT increased from 2001 to 2011 across all

clinical stages: I, 0.1% to 1.2%; II, 1.0% to 13.6%; III, 0.0% to 11.9%; and IV, 1.4% to 27.0% (All P trend < 0.001), respectively (Figure 2). In contrast, utilization decreased for MRI (P trend = 0.08) for clinical stage I, II and IV patients, while the use of CT imaging techniques remained essentially unchanged.

We used multivariable logistic regression models to evaluate factors associated with utilization of each the three imaging modalities for patients diagnosed with bladder cancer. We noted a marked increase in use of PET/CT during the study period (2011 v 2004: OR 17.55, 95% CI = 10.14–30.38, $P < 0.001$) (Table 2). Predictors associated with an increased likelihood of receiving PET/CT included female vs. male gender (OR 1.28, 95% CI 1.12–1.46, $p = 0.001$), White vs. non-White (non-Hispanic Black: OR 0.74, 95% CI 0.55–0.99, $p = 0.047$; Hispanic: OR 0.54, 95% CI 0.36–0.81, $p = 0.003$), married v single marital status (OR 1.21, 95% CI 1.01–1.45, $p = 0.034$), being diagnosed with high vs. low grade tumors (OR 1.89, 95% CI 1.56–2.28, $p < 0.001$), clinical stage higher than I (Stage I: OR 6.17, 95% CI 5.25–7.24, $p < 0.001$; Stage II: OR 5.86, 95% CI 4.67–7.35, $p < 0.001$, and Stage III: OR 11.20, 95% CI 9.39–13.35, $p < 0.001$), and the presence of hydronephrosis (yes vs. no OR 1.40, 95% CI 1.15–1.70, $p < 0.001$).

In our multivariable analysis, there was significantly decreased utilization of MRI (OR 0.60, 95% CI 0.49–0.75, $P < 0.001$) in 2011 vs. 2004, respectively. Predictors associated with increased likelihood of receiving MRI included female vs male gender (OR 1.35, 95% CI 1.21–1.50, $p < 0.001$), non-White (non-Hispanic black: OR 1.50, 95% CI 1.21–1.86, $p < 0.001$; Hispanic: OR 1.49, 95% CI 1.15–1.95, $p = 0.003$), Northwest vs. West region (OR 1.41, 95% CI 1.24–1.60, $p < 0.001$), being diagnosed with high vs. low grade tumors (OR 1.41, 95% CI 1.23–1.61, $p < 0.001$), clinical stage II, III, and IV vs. I (Stage II: OR 6.17, 95% CI 5.25–7.24, $p < 0.001$; Stage III: OR 5.86, 95% CI 4.67–7.35, $p < 0.001$, and Stage IV: OR 11.20, 95% CI 9.39–13.35, $p < 0.001$), hydronephrosis yes vs. no (OR 1.57, 95% CI 1.31–1.87, $p < 0.001$), and comorbidity score 3 or more (OR 1.38, 95% CI 1.18–1.62, $P < 0.001$).

Predictors associated with increased likelihood of receiving CT were younger age (70–74, OR 0.89, 95% CI 0.82–0.96, $P = 0.002$; 75–79, OR 0.84, 95% CI 0.78–0.90, $P < 0.001$; 80+, OR 0.72, 95% CI 0.67–0.78, $P < 0.001$; versus patients age 66–69 years old), female vs male gender (OR 1.40, 95% CI 1.32–1.48, $p < 0.001$), Hispanic vs. non-Hispanic White and non-Hispanic Black race/ethnicity (Hispanic, OR 1.19, 95% CI 1.03–1.037, $p = 0.015$), married vs. single marital status (OR 1.09, 95% CI 1.01–1.17, $p = 0.021$), highest median household income quartile (OR 1.12, 95% CI 1.04–1.20, $p = 0.002$), being diagnosed with high vs. low grade tumors (OR 1.61, 95% CI 1.52–1.69, $p < 0.001$), clinical stage II, III, and IV vs. I (Stage II: OR 3.74, 95% CI 3.39–4.13, $p < 0.001$; Stage III: OR 5.91, 95% CI 4.81–7.26, $p < 0.001$, and Stage IV: OR 6.46, 95% CI 5.42–7.70, $p < 0.001$), and hydronephrosis yes vs. no (OR 1.42, 95% CI 1.25–1.61, $p < 0.001$),

The mean incremental cost of PET/CT vs. CT and MRI was \$1,040 and \$612 (in 2016 dollars), respectively. The estimated national excess in health care costs for PET/CT imaging compared to less costlier CT and MRI techniques was \$11.6 million (Supplemental Material 3).

DISCUSSION

Guidelines recommend use of CT and MRI as the principle imaging in the staging and management of bladder cancer²⁻⁴. While there is uncertainty regarding use in metastatic patients, there are no evidence to suggest its clinical value in the non-metastatic setting⁷. In the present study, we assessed trends in use of PET/CT, MRI, and CT among bladder cancer patients. Our study revealed a significant shift in the type of imaging modality performed during the study period. Specifically, we observed marked 16-fold increased use of PET/CT regardless of clinical stage. This rapid adoption of PET/CT translated into excess national spending of approximately \$11 million.

PET/CT has become the standard of care for other malignancies due to improved sensitivity and specificity over CT or MRI.¹³⁻¹⁵ However, whether or not PET/CT improves the accuracy in bladder cancer staging is a matter of debate. When PET/CT was used in detecting the primary tumor, the reported sensitivity ranged from 54% to 86.7% with a specificity from 25% to 100%^{5, 18-20}. Conversely, the sensitivity dropped for PET/CT in preoperative staging, ranging from 46% to 60%^{16, 19, 21}. There have been only a few studies that have reported PET/CT to be more sensitive than CT for preoperative staging^{19, 22}. Although PET/CT may offer the ability to detect additional lesions and more frequently upstage patients, the final clinical impact on actual treatment changes may be relatively low and not adequately quantified in these studies^{7, 23-25}. Due to the limited number of comparative effectiveness studies available, as well as the relatively small number of patients included in these studies, current guidelines do not recommend the use of PET/CT imaging for bladder cancer staging²⁻⁴. One major challenge of using PET in bladder cancer patients is that the fluorodeoxyglucose (FDG) is excreted into the urinary system, some have refuted this benefit as an acceptable initial imaging modality for staging bladder cancer patients.^{16, 17} The recent studies have found that use of other tracers than FDG, such as C11-methionine and C11-choline, may improve the visualization of PET imaging in bladder cancer.^{26, 27} However, further research is needed to support the application of these new tracers into clinical practice.

In the present study, predictors for receipt of advanced imaging largely included clinical and pathologic determinants. Patients with high grade tumors, >T2 or greater clinical stage, and those with increased comorbidities were the most likely to receive advanced imaging. Our finding that patients who underwent chemotherapy were more likely to receive advanced imaging may reflect a higher index of suspicion for more advanced disease in this population. Moreover, we also observed geographic variation in receipt of advanced imaging. Patients residing in the western US regions were significantly more likely to receive advanced imaging. This variability in practice patterns may be a reflection of a larger number of PET/CT scanners in the western region compared to other SEER regions with inherent improved access to this imaging and/or market influences²⁸. A prior study have associated increased use of advanced imaging with physician self-referral arrangements as a major driver of health care costs²⁹. Interestingly, that study was derived from a large private insurer in California.

The cost difference between PET/CT and other imaging were substantial at a national level. Our study estimated that the excess spending on advanced imaging will impose about \$12 million in cost-expenditures. This may be an underestimate as our analysis used Medicare reimbursement rates for imaging which are historically lower than private insurance payers. The substantial economic costs of adopting advanced technology from diagnosis to treatment is an important issue of current health care reform^{30, 31}. The cost of PET was only 1.5% of the Medicare spending on cancer care, however the contribution of PET to cancer care spending will continue to increase due to the higher growth rate of imaging cost than the cost of cancer care.³² Our data highlights the need for health policy measures to limit utilization and the associated costs of advanced imaging which are not guideline-recommended over less costly imaging modalities⁹.

Our findings must be interpreted in the context of the study design. First, the SEER-Medicare database provides a national representative sample of elderly patients which findings may not be generalizable to younger populations. Second, Medicare claims data do not collect information on glomerular filtration rate and urine creatinine clearance. Both of these are determinants are often used as surrogates regarding appropriateness of using CT or MRI in patients with poor renal function. Third, claims data do not contain information regarding patient and physician preference which are important determinants in the decision-making process on imaging selection^{33, 34}. Fourth, we did not require a corresponding diagnosis code for bladder cancer when an imaging was identified since we found in the sensitivity analysis that only 20% bladder cancer patients received imaging billed with this diagnosis code which would have largely underestimated utilization of imaging. Finally, with limited clinical information available from claims data to determine the intent of advanced imaging, our study merely focused on the national trends in advanced imaging adoption. We made no attempt to discern trends in the appropriateness of the various imaging modalities used in bladder cancer. The appropriateness of various imaging modalities remains to be determined given recent guideline panel recommendations on appropriateness of use of the varying imaging modalities in bladder cancer^{4, 35, 36}.

CONCLUSIONS

We identified rapid adoption of PET/CT imaging without comparative effectiveness research documenting clinical superiority over less costlier guideline-recommended imaging. These findings have important implications regarding health policy decision-making and the need for improved value-based bladder cancer care.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

This study was conducted with the support of the Institute for Translational Sciences at the University of Texas Medical Branch, supported in part by a Clinical and Translational Science Award Mentored Career Development (KL2) Award (KL2TR001441) from the National Center for Advancing Translational Sciences, National Institutes of Health (NIH), Comparative Effectiveness Research on Cancer in Texas (CERCIT) (RP140020) and the National Cancer Institute (NCI) (K05 CA134923) (SBW). This study was funded in part by the NIH Bladder SPORE

(5P50CA091846-03) (AMK). This work was supported in part by the Duncan Family Institute and a fellowship from The University of Texas MD Anderson Cancer Center's Halliburton Employees Foundation (Huo). We thank Dr. Gary Deyter from the Department of Health Services Research at The University of Texas MD Anderson Cancer Center for reviewing and editing the manuscript. This study used the linked Surveillance, Epidemiology, and End Results (SEER)-Medicare linked database. The interpretation and reporting of these data are the sole responsibility of the authors. The authors acknowledge the efforts of the Applied Research Program, NCI; the Office of Research, Development and Information, CMS; Information Management Services (IMS), Inc.; and the SEER program tumor registries in the creation of the SEER database.

References

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. *CA: a cancer journal for clinicians*. 2016; 66:7–30. [PubMed: 26742998]
2. Clark PE, Agarwal N, Biagioli MC, et al. Bladder cancer. *J Natl Compr Canc Netw*. 2013; 11:446–475. [PubMed: 23584347]
3. Babjuk M, Bohle A, Burger M, et al. EAU Guidelines on Non-Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016. *European urology*. 2017; 71:447–461. [PubMed: 27324428]
4. Witjes JA, Compérat E, Cowan NC, et al. EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2013 Guidelines. *European urology*. 2014; 65:778–792. [PubMed: 24373477]
5. Anjos DA, Etchebehere ECSC, Ramos CD, Santos AO, Albertotti C, Camargo EE. 18F-FDG PET/CT Delayed Images After Diuretic for Restaging Invasive Bladder Cancer. *Journal of Nuclear Medicine*. 2007; 48:764–770. [PubMed: 17475965]
6. Goodfellow H, Viney Z, Hughes P, et al. Role of fluorodeoxyglucose positron emission tomography (FDG PET)-computed tomography (CT) in the staging of bladder cancer. *BJU international*. 2014; 114:389–395. [PubMed: 24341486]
7. Lu YY, Chen JH, Liang JA, et al. Clinical value of FDG PET or PET/CT in urinary bladder cancer: a systemic review and meta-analysis. *European journal of radiology*. 2012; 81:2411–2416. [PubMed: 21899971]
8. Rocque GB, Williams CP, Jackson BE, et al. Choosing Wisely: Opportunities for Improving Value in Cancer Care Delivery? *Journal of oncology practice*. 2017; 13:e11–e21. [PubMed: 27845867]
9. National Cancer Policy F, Board on Health Care S, Institute of M, National Academies of Sciences E, Medicine. Appropriate Use of Advanced Technologies for Radiation Therapy and Surgery in Oncology: Workshop Summary. Washington (DC): National Academies Press (US); 2016. The National Academies Collection: Reports funded by National Institutes of Health. Copyright 2016 by the National Academy of Sciences. All rights reserved.
10. Klabunde CN, Potosky AL, Legler JM, Warren JL. Development of a comorbidity index using physician claims data. *Journal of Clinical Epidemiology*. 2000; 53:1258–1267. [PubMed: 11146273]
11. Charlson ME, Sax FL, MacKenzie CR, Fields SD, Braham RL, Douglas RG. Assessing illness severity: does clinical judgment work? *J Chronic Dis*. 1986; 39:439–452. [PubMed: 3086355]
12. Mauchley DC, Mitchell JD. Current estimate of costs of lung cancer screening in the United States. *Thoracic Surgery Clinics*. 2015; 25:205–215. [PubMed: 25901564]
13. Agrawal A, Rangarajan V. Appropriateness criteria of FDG PET/CT in oncology. *The Indian Journal of Radiology & Imaging*. 2015; 25:88–101. [PubMed: 25969632]
14. International Atomic Energy Agency. A Guide to Clinical PET in Oncology: Improving Clinical Management of Cancer Patients. 2017 IAEA-TECDOC-1605 ed2008.
15. Delbeke D, Coleman RE, Guiberteau MJ, et al. Procedure guideline for tumor imaging with 18F-FDG PET/CT 1.0. *Journal of nuclear Medicine*. 2006; 47:885–895. [PubMed: 16644760]
16. Swinnen G, Maes A, Pottel H, et al. FDG-PET/CT for the Preoperative Lymph Node Staging of Invasive Bladder Cancer. *European urology*. 2010; 57:641–647. [PubMed: 19477579]
17. Schöder, H., Larson, SM. Seminars in nuclear medicine. Vol. 34. Elsevier; 2004. Positron emission tomography for prostate, bladder, and renal cancer; p. 274-292.

18. Harkirat S, Anand S, Jacob M. Forced diuresis and dual-phase ¹⁸F-fluorodeoxyglucose-PET/CT scan for restaging of urinary bladder cancers. *Indian Journal of Radiology and Imaging*. 2010; 20:13–19. [PubMed: 20351986]
19. Lodde M, Lacombe L, Friede J, Morin F, Saourine A, Fradet Y. Evaluation of fluorodeoxyglucose positron-emission tomography with computed tomography for staging of urothelial carcinoma. *BJU international*. 2010; 106:658–663. [PubMed: 20151968]
20. Lu Y-Y, Chen J-H, Liang J-A, et al. Clinical value of FDG PET or PET/CT in urinary bladder cancer: A systemic review and meta-analysis. *European journal of radiology*. 2012; 81:2411–2416. [PubMed: 21899971]
21. Drieskens O, Oyen R, Van Poppel H, Vankan Y, Flamen P, Mortelmans L. FDG-PET for preoperative staging of bladder cancer. *European Journal of Nuclear Medicine and Molecular Imaging*. 2005; 32:1412–1417. [PubMed: 16133380]
22. Apolo AB, Riches J, Schöder H, et al. Clinical Value of Fluorine-18 2-Fluoro-2-Deoxy-D-Glucose Positron Emission Tomography/Computed Tomography in Bladder Cancer. *Journal of Clinical Oncology*. 2010; 28:3973–3978. [PubMed: 20679618]
23. Mertens LS, Fioole-Bruining A, Vegt E, Vogel WV, van Rhijn BW, Horenblas S. Impact of 18F-fluorodeoxyglucose (FDG)-positron-emission tomography/computed tomography (PET/CT) on management of patients with carcinoma invading bladder muscle. *BJU international*. 2013; 112:729–734. [PubMed: 23790129]
24. Goodfellow H, Viney Z, Hughes P, et al. Role of fluorodeoxyglucose positron emission tomography (FDG PET)-computed tomography (CT) in the staging of bladder cancer. *BJU International*. 2014; 114:389–395. [PubMed: 24341486]
25. Kibel AS, Dehdashti F, Katz MD, et al. Prospective Study of [(18)F]Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography for Staging of Muscle-Invasive Bladder Carcinoma. *Journal of Clinical Oncology*. 2009; 27:4314–4320. [PubMed: 19652070]
26. de Jong IJ, Pruim J, Elsinga PH, Jongen MM, Mensink HJ, Vaalburg W. Visualisation of bladder cancer using 11C-choline PET: first clinical experience. *European Journal of Nuclear Medicine and Molecular Imaging*. 2002; 29:1283–1288. [PubMed: 12271408]
27. Schöder H, Larson SM. Positron emission tomography for prostate, bladder, and renal cancer. *Seminars in Nuclear Medicine*. 2004; 34:274–292. [PubMed: 15493005]
28. Buck AK, Herrmann K, Stargardt T, Dechow T, Krause BJ, Schreyögg J. Economic Evaluation of PET and PET/CT in Oncology: Evidence and Methodologic Approaches. *Journal of Nuclear Medicine Technology*. 2010; 38:6–17. [PubMed: 20197541]
29. Mitchell JM. Utilization trends for advanced imaging procedures: evidence from individuals with private insurance coverage in California. *Medical care*. 2008; 46:460–466. [PubMed: 18438193]
30. Dinan MA, Curtis LH, Hammill BG, et al. Changes in the use and costs of diagnostic imaging among medicare beneficiaries with cancer, 1999–2006. *JAMA*. 2010; 303:1625–1631. [PubMed: 20424253]
31. Nguyen PL, Gu X, Lipsitz SR, et al. Cost Implications of the Rapid Adoption of Newer Technologies for Treating Prostate Cancer. *Journal of Clinical Oncology*. 2011; 29:1517–1524. [PubMed: 21402604]
32. Yang Y, Czernin J. Contribution of Imaging to Cancer Care Costs. *Journal of Nuclear Medicine*. 2011; 52:86S–92S. [PubMed: 22144560]
33. Barry MJ, Edgman-Levitan S. Shared Decision Making — The Pinnacle of Patient-Centered Care. *New England Journal of Medicine*. 2012; 366:780–781. [PubMed: 22375967]
34. Gogineni K, Shuman KL, Chinn D, Gabler NB, Emanuel EJ. Patient demands and requests for cancer tests and treatments. *JAMA Oncology*. 2015; 1:33–39. [PubMed: 26182301]
35. NCCN Bladder Cancer Practice Guidelines (Version 2.2016). Williston Park, N.Y: The National Comprehensive Cancer Network; 2016.
36. Milowsky MI, Rumble RB, Booth CM, et al. Guideline on Muscle-Invasive and Metastatic Bladder Cancer (European Association of Urology guideline): American Society of Clinical Oncology Clinical Practice Guideline Endorsement. *Journal of Clinical Oncology*. 2016

CLINICAL PRACTICE POINTS

- Current European and United States Guidelines on bladder cancer recommend CT and/or MRI as the preferred abdominal imaging modality over the PET/CT in preoperative staging and follow-up surveillance.
- The American Board of Internal Medicine's Choosing Wisely campaign and American Society of Clinical Oncology's Value of Cancer Care Task Force have collaborated to encourage sustainable high-quality and high-value based cancer care.
- Data from this large population-based cancer registry analysis of utilization patterns and economic impact regarding advanced imaging in bladder cancer showed a sharp increase in the use of advanced PET/CT imaging during the study period, accompanied with an excess national spending of approximately \$11 million.
- These findings suggested that value-based bladder cancer care is needed in community practice. Researches on comparative effectiveness of PET/CT imaging over less costlier imaging techniques are lacking to support contemporary trend of PET/CT imaging.

Figure 1.

Percent of patients receiving any imaging, CT, MRI, and PET/CT, after bladder cancer diagnosis from 2004–2011 (Any imaging: Ptrend, <0.001; CT: Ptrend, P <0.001; MRI: Ptrend, P <0.001; PET/CT: Ptrend, <0.001).

Figure 2.

Percent of patients receiving PET/CT, MRI, or CT imaging after a bladder cancer diagnosis.

A). PET/CT (Stage I: Cochrane Armitage test of trend, $P < 0.001$; Stage II: Cochrane Armitage test of trend, $P < 0.001$; Stage III: Ptrend, $P < 0.001$; Stage IV: Ptrend, $P < 0.001$)
 B). MRI (Stage I: Ptrend, $P = 0.001$; Stage II: Ptrend, $P < 0.001$; Stage III: Ptrend, $P = 0.083$; Stage IV: Ptrend, $P = 0.031$). C). CT (Stage I: Ptrend, $P < 0.001$; Stage II: Ptrend, $P = 0.379$; Stage III: Ptrend, $P = 0.658$; Stage IV: Ptrend, $P = 0.480$).

Table 1

Patient demographic and clinical characteristics by the type of imaging

Characteristic	PET/CT (%)			MRI (%)			CT (%)		
	Yes	No	p	Yes	No	p	Yes	No	p
Year of Diagnosis			<0.001			<0.001			<0.001
2004	14 (1.1)	5138 (14.4)		250 (15.1)	4902 (13.9)		2932 (12.3)	2220 (17.0)	
2005	41 (3.2)	4807 (13.5)		244 (14.8)	4604 (13.1)		2948 (12.4)	1900 (14.6)	
2006	160 (12.4)	4452 (12.5)		263 (15.9)	4349 (12.4)		2985 (12.5)	1627 (12.5)	
2007	159 (12.3)	4481 (12.6)		220 (13.3)	4420 (12.6)		3040 (12.8)	1600 (12.3)	
2008	226 (17.5)	4358 (12.3)		201 (12.2)	4383 (12.5)		3092 (13.0)	1492 (11.4)	
2009	246 (19.1)	4087 (11.5)		139 (8.4)	4194 (11.9)		2996 (12.6)	1337 (10.3)	
2010	259 (20.1)	4202 (11.8)		200 (12.1)	4261 (12.1)		3029 (12.7)	1432 (11.0)	
2011	186 (14.4)	4039 (11.4)		134 (8.1)	4091 (11.6)		2801 (11.8)	1424 (10.9)	
Age Group			0.002			0.001			<0.001
66–69	219 (17.0)	5464 (15.4)		256 (15.5)	5427 (15.4)		3837 (16.1)	1846 (14.2)	
70–74	288 (22.3)	7986 (22.5)		432 (26.2)	7842 (22.3)		5387 (22.6)	2887 (22.2)	
75–79	356 (27.6)	8668 (24.4)		404 (24.5)	8620 (24.5)		5822 (24.4)	3202 (24.6)	
80+	428 (33.2)	13446 (37.8)		559 (33.9)	13315 (37.8)		8777 (36.8)	5097 (39.1)	
Sex			<0.001			<0.001			<0.001
Male	865 (67.0)	26424 (74.3)		1088 (65.9)	26201 (74.4)		17066 (71.6)	10223 (78.4)	
Female	426 (33.0)	9140 (25.7)		563 (34.1)	9003 (25.6)		6757 (28.4)	2809 (21.6)	
Race			0.474			<0.001			0.033
Non-Hispanic White	1151 (89.2)	31576 (88.8)		1405 (85.1)	31322 (89.0)		21119 (88.6)	11608 (89.1)	
Non-Hispanic Black	53 (4.1)	1440 (4.0)		110 (6.7)	1383 (3.9)		984 (4.1)	509 (3.9)	
Hispanic	28 (2.2)	1026 (2.9)		67 (4.1)	987 (2.8)		720 (3.0)	334 (2.6)	
Other	59 (4.6)	1522 (4.3)		69 (4.2)	1512 (4.3)		1000 (4.2)	581 (4.5)	
Marital Status			0.533			0.469			0.003
Single	182 (14.1)	4638 (13.0)		226 (13.7)	4594 (13.0)		3133 (13.2)	1687 (12.9)	
Married	763 (59.1)	21195 (59.6)		960 (58.1)	20998 (59.6)		14048 (59.0)	7910 (60.7)	
Unknown	346 (26.8)	9731 (27.4)		465 (28.2)	9612 (27.3)		6642 (27.9)	3435 (26.4)	
Census Region			<0.001			<0.001			<0.001

Characteristic	PET/CT (%)			MRI (%)			CT (%)		
	Yes	No	p	Yes	No	p	Yes	No	p
West	598 (46.3)	13933 (39.2)		622 (37.7)	13909 (39.5)		9171 (38.5)	5360 (41.1)	
Northeast	257 (19.9)	8984 (25.3)		543 (32.9)	8698 (24.7)		5978 (25.1)	3263 (25.0)	
Midwest	97 (7.5)	4207 (11.8)		163 (9.9)	4141 (11.8)		2725 (11.4)	1579 (12.1)	
South	339 (26.3)	8440 (23.7)		323 (19.6)	8456 (24.0)		5949 (25.0)	2830 (21.7)	
Urban/Rural			0.501			0.050			0.955
Urban	1261 (97.7)	34834 (97.9)		1628 (98.6)	34467 (97.9)		23331 (97.9)	12764 (97.9)	
Rural	30 (2.3)	730 (2.1)		23 (1.4)	737 (2.1)		492 (2.1)	268 (2.1)	
Median Household Income, \$			0.256			<0.001			0.736
<= 23,364	346 (26.8)	9335 (26.2)		359 (21.7)	9322 (26.5)		6276 (26.3)	3405 (26.1)	
23,365 – 31,906	336 (26.0)	8729 (24.5)		403 (24.4)	8662 (24.6)		5834 (24.5)	3231 (24.8)	
31,907 – 41,719	288 (22.3)	8762 (24.6)		453 (27.4)	8597 (24.4)		5825 (24.5)	3225 (24.7)	
>= 41,720	321 (24.9)	8738 (24.6)		436 (26.4)	8623 (24.5)		5888 (24.7)	3171 (24.3)	
Stage			<0.001			<0.001			<0.001
I	413 (32.0)	29155 (82.0)		912 (55.2)	28656 (81.4)		17326 (72.7)	12242 (93.9)	
II	424 (32.8)	3768 (10.6)		349 (21.1)	3843 (10.9)		3648 (15.3)	544 (4.2)	
III	125 (9.7)	1103 (3.1)		136 (8.2)	1092 (3.1)		1125 (4.7)	103 (0.8)	
IV	329 (25.5)	1538 (4.3)		254 (15.4)	1613 (4.6)		1724 (7.2)	143 (1.1)	
Hydronephrosis			<0.001			<0.001			<0.001
No	1141 (88.4)	34017 (95.7)		1488 (90.1)	33670 (95.6)		22487 (94.4)	12671 (97.2)	
Yes	150 (11.6)	1547 (4.3)		163 (9.9)	1534 (4.4)		1336 (5.6)	361 (2.8)	
Grade			<0.001			<0.001			<0.001
Low	167 (12.9)	14341 (40.3)		421 (25.5)	14087 (40.0)		8027 (33.7)	6481 (49.7)	
High	1028 (79.6)	15851 (44.6)		1061 (64.3)	15818 (44.9)		12631 (53.0)	4248 (32.6)	
Unknown	96 (7.4)	5372 (15.1)		169 (10.2)	5299 (15.1)		3165 (13.3)	2303 (17.7)	
Comorbidity Score			0.293			0.006			0.000
0	671 (52.0)	18505 (52.0)		824 (49.9)	18352 (52.1)		12328 (51.7)	6848 (52.5)	
1	336 (26.0)	9150 (25.7)		428 (25.9)	9058 (25.7)		6289 (26.4)	3197 (24.5)	
2	132 (10.2)	4134 (11.6)		181 (11.0)	4085 (11.6)		2744 (11.5)	1522 (11.7)	
3+	152 (11.8)	3775 (10.6)		218 (13.2)	3709 (10.5)		2462 (10.3)	1465 (11.2)	
Radical Cystectomy			<0.001			<0.001			<0.001

Characteristic	PET/CT (%)			MRI (%)			CT (%)		
	Yes	No	p	Yes	No	p	Yes	No	p
Characteristic									
No	1009 (78.2)	33485 (94.2)		1372 (83.1)	33122 (94.1)		21527 (90.4)	12967 (99.5)	
Yes	282 (21.8)	2079 (5.8)		279 (16.9)	2082 (5.9)		2296 (9.6)	65 (0.5)	
Chemotherapy			<0.001			<0.001			<0.001
No	712 (55.2)	33194 (93.3)		1278 (77.4)	32628 (92.7)		21120 (88.7)	12786 (98.1)	
Yes	579 (44.8)	2370 (6.7)		373 (22.6)	2576 (7.3)		2703 (11.3)	246 (1.9)	
Radiation therapy			<0.001			<0.001			<0.001
No	1043 (80.8)	34398 (96.7)		1456 (88.2)	33985 (96.5)		22453 (94.2)	12988 (99.7)	
Yes	248 (19.2)	1166 (3.3)		195 (11.8)	1219 (3.5)		1370 (5.8)	44 (0.3)	

Multivariable model discerning predictors for receipt of positron emission tomography–computed tomography, magnetic resonance imaging and computed tomography

Table 2

Characteristic	PET/CT			MRI			CT		
	OR	95% CI	P-value	OR	95% CI	P-value	OR	95% CI	P-value
Year of Diagnosis									
2004	1.00			1.00			1.00		
2005	3.00	1.63 5.52	<.001	1.02	0.84 1.22	0.877	1.16	1.06 1.26	<.001
2006	13.30	7.67 23.07	<.001	1.15	0.96 1.38	0.136	1.39	1.28 1.51	<.001
2007	13.25	7.64 22.98	<.001	0.95	0.79 1.15	0.591	1.46	1.34 1.59	<.001
2008	19.89	11.54 34.29	<.001	0.86	0.71 1.04	0.119	1.60	1.47 1.75	<.001
2009	23.94	13.90 41.22	<.001	0.62	0.50 0.77	<.001	1.73	1.59 1.89	<.001
2010	25.21	14.65 43.39	<.001	0.89	0.74 1.09	0.261	1.69	1.55 1.85	<.001
2011	17.55	10.14 30.38	<.001	0.60	0.49 0.75	<.001	1.55	1.42 1.70	<.001
Age Group									
66–69	1.00			1.00			1.00		
70–74	0.91	0.76 1.10	0.348	1.16	0.98 1.36	0.08	0.89	0.82 0.96	0.002
75–79	1.04	0.86 1.25	0.694	0.92	0.78 1.08	0.31	0.84	0.78 0.90	<.001
80+	0.66	0.55 0.79	<.001	0.76	0.65 0.89	<.001	0.72	0.67 0.78	<.001
Sex									
Male	1.00			1.00			1.00		
Female	1.28	1.12 1.46	<.001	1.35	1.21 1.50	<.001	1.40	1.32 1.48	<.001
Race									
Non-Hispanic White	1.00			1.00			1.00		
Non-Hispanic Black	0.74	0.55 0.99	0.047	1.50	1.21 1.86	<.001	0.86	0.76 0.97	0.012
Hispanic	0.54	0.36 0.81	0.003	1.49	1.15 1.95	0.003	1.19	1.03 1.37	0.015
Other	0.86	0.64 1.14	0.287	0.94	0.73 1.21	0.615	0.95	0.85 1.06	0.327
Marital Status									
Single	1.00			-			1.00		
Married	1.21	1.01 1.45	0.034	-			1.09	1.01 1.17	0.021
Unknown	1.06	0.87 1.30	0.558	-			1.06	0.98 1.15	0.128

Characteristic	PET/CT			MRI			CT		
	OR	95% CI	P-value	OR	95% CI	P-value	OR	95% CI	P-value
Census Region									
West	1.00			1.00			1.00		
Northeast	0.71	0.61 0.83	<.001	1.41	1.24 1.60	<.001	1.11	1.04 1.17	0.001
Midwest	0.50	0.40 0.63	<.001	0.89	0.74 1.07	0.215	1.05	0.98 1.14	0.179
South	0.94	0.81 1.08	0.37	0.89	0.77 1.03	0.128	1.30	1.22 1.39	<.001
Median Household Income, \$									
<= 23,364	-			1.00			1.00		
23,365 – 31,906	-			1.18	1.01 1.37	0.038	1.04	0.98 1.11	0.207
31,907 – 41,719	-			1.25	1.07 1.47	0.005	1.07	1.00 1.14	0.065
>= 41,720	-			1.21	1.03 1.43	0.019	1.12	1.04 1.20	0.002
Grade									
Low	1.00			1.00			1.00		
High	1.89	1.56 2.28	<.001	1.41	1.23 1.61	<.001	1.61	1.52 1.69	<.001
Unknown	0.94	0.72 1.22	0.641	1.07	0.88 1.29	0.506	0.97	0.91 1.04	0.44
Clinical Stage									
I	1.00			1.00			1.00		
II	6.17	5.25 7.24	<.001	2.41	2.09 2.78	<.001	3.74	3.39 4.13	<.001
III	5.86	4.67 7.35	<.001	3.14	2.57 3.85	<.001	5.91	4.81 7.26	<.001
IV	11.20	9.39 13.35	<.001	3.88	3.29 4.56	<.001	6.46	5.42 7.70	<.001
Hydronephrosis									
No	1.00			1.00			1.00		
Yes	1.40	1.15 1.70	<.001	1.57	1.31 1.87	<.001	1.42	1.25 1.61	<.001
Comorbidity Score									
0	-			1.00			1.00		
1	-			1.08	0.96 1.22	0.209	1.12	1.07 1.19	<.001
2	-			1.04	0.88 1.23	0.64	1.03	0.96 1.11	0.456
3+	-			1.38	1.18 1.62	<.001	0.93	0.86 1.00	0.059